Abstract | PURPOSE: Although hypogonadism is a rare cause of erectile failure, impotent men are frequently treated with supplemental androgens. The results of such treatment and the individual merits of available formulations remain controversial. A series of hypogonadal men participated in a trial of oral testosterone undecanoate to assess the effectiveness of the medication, and use of biochemical and clinical outcome measures. MATERIALS AND METHODS: RESULTS:
Testosterone undecanoate produced restoration of plasma testosterone levels in all patients but a measurable improvement in sexual attitudes and performance in only 61%. Visual analogue scores were effective discriminants of the therapeutic response but none of the conventional biochemical measures predicted or correlated with clinical outcome. CONCLUSIONS:
Testosterone undecanoate is an effective agent for treating hypogonadism. In hypogonadal impotent patients the most appropriate outcome measure for androgen supplementation is individual response to therapy, while conventional biochemical hormone determinations lack predictive value and fail to correlate with response.
|
Authors | A Morales, B Johnston, J P Heaton, M Lundie |
Journal | The Journal of urology
(J Urol)
Vol. 157
Issue 3
Pg. 849-54
(Mar 1997)
ISSN: 0022-5347 [Print] United States |
PMID | 9072584
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Testosterone Congeners
- Testosterone
- testosterone undecanoate
- Methyltestosterone
|
Topics |
- Adult
- Aged
- Erectile Dysfunction
(blood, drug therapy, etiology)
- Humans
- Hypogonadism
(blood, complications, drug therapy)
- Libido
(drug effects)
- Male
- Methyltestosterone
(pharmacology)
- Middle Aged
- Testosterone
(analogs & derivatives, blood, therapeutic use)
- Testosterone Congeners
(pharmacology, therapeutic use)
|